Caplin Point Unit Gets USFDA Nod for $26M Desmopressin Injection

HEALTHCAREBIOTECH
Whalesbook Logo
AuthorAkshat Lakshkar|Published at:
Caplin Point Unit Gets USFDA Nod for $26M Desmopressin Injection
Overview

Caplin Point Laboratories' subsidiary, Caplin Steriles, has secured final USFDA approval for its Desmopressin Acetate Injection USP. This generic drug, used for haemophilia and diabetes insipidus, targets a US market with $26 million in sales. The approval is a significant step for Caplin Steriles, opening access to the lucrative US market and expected to boost revenue for the parent company.

Caplin Steriles Secures Key USFDA Approval for Desmopressin Injection

The US market for Desmopressin Acetate Injection recorded sales of approximately $26 million for the 12 months ending December 2025. Caplin Steriles Limited, a subsidiary of Caplin Point Laboratories, has now received final USFDA approval for its generic Desmopressin Acetate Injection USP.
Reader Takeaway: USFDA approval unlocks $26M market; execution risk for launch remains.

What just happened (today’s filing)

Caplin Steriles Limited, a wholly-owned subsidiary of Caplin Point Laboratories, announced on February 28, 2026, that it has received final approval from the United States Food and Drug Administration (USFDA).

The approval is for Desmopressin Acetate Injection USP. This generic drug is used for treating conditions such as haemophilia A and diabetes insipidus.

The US market for this specific product category had sales figures of approximately $26 million for the 12 months concluding in December 2025.

Why this matters

This USFDA nod grants Caplin Steriles direct access to the significant and lucrative US pharmaceutical market for this particular injectable.

It represents a crucial step in Caplin Steriles' strategy to enter regulated markets, potentially contributing substantially to the revenue growth of its parent company, Caplin Point Laboratories.

The backstory (grounded)

Caplin Point Laboratories has historically focused on emerging markets like Latin America and Africa. However, it has been strategically expanding its presence in regulated markets through its subsidiary Caplin Steriles.

Caplin Steriles has been building a pipeline of USFDA-approved products. This includes prior approvals for an ophthalmic suspension in Q3 FY23 and other generic injectables in recent years, showcasing a consistent effort to tap into markets like the US.

What changes now

  • Caplin Steriles gains market entry for Desmopressin Acetate Injection USP in the United States.
  • The company can now plan for the commercial launch of the product.
  • This approval diversifies Caplin Point Laboratories' revenue streams and geographical focus.

Risks to watch

  • Generic competition within the US market for Desmopressin Acetate Injection.
  • Challenges associated with commercial launch, distribution, and market penetration.
  • Maintaining regulatory compliance for manufacturing and sales in the US.

Peer comparison

Caplin Steriles' entry into the US injectables market places it alongside established players. Gland Pharma, a prominent sterile injectables manufacturer, has a strong US presence and multiple USFDA-approved facilities, deriving a significant portion of its revenue from this market.

Laurus Labs is also expanding its formulations business, including in therapeutic areas with injectable products, indicating a competitive landscape.

Context metrics (time-bound)

  • Caplin Point Laboratories reported consolidated revenue of approximately ₹1,100 crore for the fiscal year ended March 2025.
  • Consolidated net profit for the same period stood at approximately ₹180 crore. [cite:Screener]

What to track next

  • The timeline and execution of the commercial launch of Desmopressin Acetate Injection USP in the US.
  • Initial sales performance and market share capture post-launch.
  • Future updates on Caplin Steriles' US pipeline and potential for further approvals.
  • Commentary from Caplin Point Laboratories management on the strategic importance and expected contribution of this product.
Disclaimer:This content is for educational and informational purposes only and does not constitute investment, financial, or trading advice, nor a recommendation to buy or sell any securities. Readers should consult a SEBI-registered advisor before making investment decisions, as markets involve risk and past performance does not guarantee future results. The publisher and authors accept no liability for any losses. Some content may be AI-generated and may contain errors; accuracy and completeness are not guaranteed. Views expressed do not reflect the publication’s editorial stance.